Dr. Karen C. Johnson led University of Tennessee’s participation in the Vitamin D and Type 2 diabetes (D2d) study which found that vitamin D supplementation does not significantly reduce the likelihood of development type 2 diabetes in individuals with adequate levels of vitamin D but at high risk of the disease.
The Daily Memphian reports that Dr. Johnson was among the principal investigators of the six year nationwide diabetes prevention clinical trial that recently released findings at the American Diabetes Association’s 79thScientific Sessions in San Francisco. The findings were published online in the New England Journal of Medicine.
Observational studies had indicated vitamin D might prevent the development of type 2 diabetes, but had not been tested in a clinical trial reported Dr. Johnson. She led the UTHSC site for the D2d study, which enrolled and followed 32 individuals since 2013.
Participants were given 4,000 international units of vitamin D per day or a matching placebo. They received blood tests twice a year for an average of 2.5 years to monitor for the development of diabetes. Those receiving vitamin D evidenced no sign of negative effects from the supplementation, but the vitamin D did not reduce the risk of diabetes by the target level of 25% or more in the study population.
Investigator Karen Johnson Brings in Over $50 Million for Research
Dr. Johnson has brought more than $50 million to UTHSC in NIH funding for research as a principal investigator, and more than $45 million in NIH and Department of Defense research as a co-investigator. Her bio can be viewed here.